- WTO at 20: Symposium on the TRIPS Agreement for TRIPS Council Members and Observers (26 February 2015)
- St Jude's influenza patents, with US government rights
- CDC FOIA regarding intellectual property on avian flu intellectual property rights
- KEI Special 301 supplemental comments: Compulsory Licensing not restricted to "Emergencies" or "Measure of Last Resort"
- KEI's supplemental comments in USTR 301: Online pharmacies, parallel trade and counterfeit drugs
- KEI's Feb 27, 2015 Supplemental Comments to USTR Regarding Research and Development
- WTO TRIPS Council (February 2015): EU mounts defense of tobacco plain packing measures in the Republic of Ireland and the UK
- A few reactions to the USTR Special 301 Hearing
- KEI comments at February 24, 2015 USTR Special 301 Hearing
- WTO TRIPS Council (February 2015): Bangladesh statement (on behalf of LDC Group)- Extension of the 2016 transitional period
WIPO patent committee engaged in heated talks on work sharing, limitations & exceptions, client confidentialitySubmitted by thiru on 6. November 2014 - 11:38
6 November 2014
The following intervention on patents and health was delivered by KEI during the 21st session on WIPO's Standing Committee on the Law of Patents (SCP). Part 1 was delivered on 4 November 2014 during discussions of the Feasibility Study on the Disclosure of International Nonproprietary Names (INN) in Patent Applications and/or Patents. Part 2 was delivered on 5 November 2014 during general discussions on patents and health.
Statement of Knowledge Ecology International (KEI)
Item 7: Patents and health
On Wednesday, 5 November 2014, Pakistan delivered the following intervention on patents and health.
Agenda 7 Statement on patents and health
1. General statement
I will make this statement in national capacity,
WIPO Standing Committee on the Law of Patents (SCP 21): Intervention of Pakistan on Opposition SystemsSubmitted by thiru on 4. November 2014 - 13:29
On Tuesday, 5 November 2014, Pakistan delivered the following intervention on opposition systems.
The agenda item on quality of patents also include another item on "opposition systems" which was not discussed by the Committee. I want to make a small statement on opposition systems.
WIPO patent committee (SCP21) to discuss International Nonproprietary Names and Exceptions and Limitations to Patent RightsSubmitted by thiru on 3. November 2014 - 5:55
In the words of the International Bureau of the World Intellectual Property Organization (WIPO), the WIPO Standing Committee on the Law of Patents (SCP) was created,
created in 1998 to serve as a forum to discuss issues, facilitate coordination and provide guidance concerning the progressive international development of patent law.
WTO TRIPS Council (October 2014): Statement of India on the Review of the Paragraph 6 system (compulsory licensing for export)Submitted by thiru on 29. October 2014 - 11:49
On 28 October 2014, India delivered the following intervention at the WTO TRIPS Council's annual review of the Paragraph 6 system (designed to facilitate compulsory licensing for export of pharmaceuticals).
In particular, India noted that
Obama officials seek end of WIPO program on limitations and exceptions to patent rights in developing countriesSubmitted by Staff on 24. October 2014 - 8:21
During the WIPO 2014 General Assembly's discussions of patents and health in the context of the work of the Standing Committee on the Law of Patent (SCP), the Obama Administration embraced an aggressive position against WIPO technical assistance on the use of patent limitations and exceptions.
India's Department of Industrial Policy and Promotion creates IPR Think Tank to Draft National IPR PolicySubmitted by thiru on 24. October 2014 - 6:05
On Friday, 24 October 2014, India's Department of Industrial Policy and Promotion (DIPP) announced the creation of an IPR Think Tank to Draft National Intellectual Property Rights Policy.
The composition of the think tank follows:
Justice Prabha Sridevan, Chairperson, IPR Think Tank;
Ms. Pratibha Singh, Advocate, Singh & Singh Associates, Member;
Ms. Punita Bhargava, Advocate, Inventure IP, Member;
Dr. Unnat Pandit, Cadila Pharmaceuticals Limited, Member;
|Ambassador Michael Froman wants to block compulsory licenses on drug patents in India|
New leak of TPP consolidated text on intellectual property provides details of pandering to drug companies and publishersSubmitted by James Love on 16. October 2014 - 5:03
For more information:
James Love, Knowledge Ecology International
email: email@example.com, +1.202.361.3040
The May 16, 2014 version of the consolidated negotiating text for the Intellectual Property Chapter for the Trans-Pacific Partnership (TPP) agreement is a long, complex document that taken as a whole is designed to expand and extend monopolies on knowledge goods, including in particular publisher-owned copyrights, patents on inventions, and monopoly rights in data used to register new drugs, vaccines and agricultural chemical products.
UPDATE: TRIPS Council (Oct. 2014): Ukraine requests discussion on compatibility of tobacco plain packaging measures with TRIPSSubmitted by thiru on 6. October 2014 - 0:05
UPDATE: On 17 October 2014, the Secretariat of the World Trade Organization (WTO) circulated an updated WTO airgram WTO/AIR/4358 REV. 1 to its Members following a request by Ukraine. Ukraine requested the addition of an item on "Concerns with Respect to Measures Related to Plain Packaging of Tobacco Products and their Compatibility with the TRIPS Agreement." This will be discussed under agenda item 13.
From the TTIP Stakeholder Forum.
The 7th Round of the negotiations of the Transatlantic Trade and Investment Partnership (TTIP) Agreement began Monday September 29, 2014 in the United States. This round's paltry effort at transparency, the TTIP Stakeholder Engagement Day, was held at the suburban 4-H conference center in Chevy Chase, MD. Although the information packet for the event included public transport instructions, the location was difficult to access for any attendees without a car, and even then, parking was extremely limited.
KEI was asked to make a presentation on Hepatitis C, on September 30, 2014, at a lunch seminar at UNITAID. I am attaching a PDF of the slides I used, as well as an eight page memo that takes a look at the recent Gilead license. The memo on the license was last edited on September 30, 2014, and is presented as a draft that may be revised in the future.